Targeted new approach to treat pancreatic cancer Scientists transform genetic culprit behind treatment resistance into a skillful tool to use against cancer Date: April 8, 2025 Source: City of ...

ALX2004 is a potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors that was created from ALX Oncology’s proprietary linker-payload ...

1Department of Pathology, Yale University School of Medicine, New Haven, Connecticut. 2Department of Internal Medicine, National and Kapodistrian University of Athens, School of Medicine, Sotiria ...

The availability of MSD’s vaccine in individual nations will be subject to various factors. Credit: Copyright © 2025 Merck & Co., Inc., Rahway, NJ, USA and its ...

Novel trispecific T cell engager, ZW209, demonstrates potent preclinical efficacy against DLL3-expressing tumors and an encouraging safety profile New antibody-drug conjugate (ADC) candidate ...

New antibody-drug conjugate (ADC) candidate, ZW327, exhibits anti-tumor activity and a favorable pharmacokinetics profile in Ly6E-bearing cancers VANCOUVER, British Columbia, March 25, 2025 (GLOBE ...